Chapter 434 - 261: Academician Zeng’s Promise and Teacher Wu’s Training Camp (2)
Chapter 434: Chapter 261: Academician Zeng’s Promise and Teacher Wu’s Training Camp (2)
Listening to Director Fu’s vision, the other directors present felt their hearts pound with excitement.
If they succeeded, it would mean the complete eradication of hepatitis B-related primary liver cancer, a disease that plagued countless families!
Ma Mengchao was momentarily taken aback by the directors’ idea. After thinking it over, he too endorsed this grand plan.
"Alright. I’ll organize my thoughts and contact Teacher Zeng immediately."
Ma Mengchao was decisive. A short while later, he was on the phone with Scholar Zeng Jiu.
Scholar Zeng’s generation of old medical experts were the ones who had built the Jin Country’s medical system from scratch. They had dedicated their entire lives to it and had now reached the age of passing the baton. As such, they were extremely welcoming and supportive of the new ideas and approaches from the younger generation.
Scholar Zeng held a brief, impromptu meeting with the directors.
"Meng Chao, Bo Feng, Jinfen... I fully support your idea."
"This Dr. Wu Ting is indeed a brilliantly talented and imaginative new-generation medical professional. I agree with your plan."
"After this year’s annual conference, our generation of old-timers was already due to step down. The future of the medical world will depend on you, the cornerstones, and the rising generation like Wu Ting to carry the torch forward."
"Then let’s proceed according to your plan. We’ll start with a pilot program coordinated among the four hospitals in the Yangtze River Delta."
"Let’s set the annual conference of the Jin Country Medical Association’s surgical branch as our deadline. If you can produce sufficient supporting data and research results by then, I will propose the formation of this national Hepatic Tumor Surgery group."
"The group will be centered on creating our very own Jin Country technique for the complete radical cure of hepatitis B-related primary liver cancer, as well as the corresponding clinical guidelines."
Scholar Zeng had a good impression of Wu Ting and held equally high hopes for this project.
"However, this will not be an easy task. There’s a long road ahead. Dr. Wu Ting is still too young, after all. I can only hope he can mature quickly."
"Otherwise, for his own protection, after the Hepatic Tumor Surgery group is formed, we will still need to select a highly respected, mid-career director to temporarily serve as the group leader, with Wu Ting as the deputy leader to push this matter forward."
Scholar Zeng glanced at his student, Ma Mengchao, who understood his teacher’s intentions.
Ma Mengchao would not shirk this responsibility. He would step up to protect and guide Wu Ting, temporarily serving as the group leader until Wu Ting was ready.
In the meeting room today, these directors were all close with Wu Ting. They knew him inside and out and were convinced he should be the leader. But once a national Hepatic Tumor Surgery group was formed, with so many top experts and professors from all over the country, would Wu Ting’s qualifications and academic standing be enough to command their respect?
The answer was obvious. Unless Wu Ting could produce astounding results in a short period, win major awards, or achieve an epoch-making breakthrough, he would lack the prestige and power to win over the nation’s top experts.
For example, wouldn’t he need to be even more accomplished than mid-career experts like Ma Mengchao and Chen Bofeng?
All Wu Ting had to his name right now were a few papers in *Cell* and *Lancet*, a youth fund project, a key project from the National Nature Science Foundation, and the new drug, Fengmu Tiada, which had just entered clinical trials.
For a new-generation doctor of Wu Ting’s age, these achievements were impressive and dazzling. But compared to the mid-career generation, he was still a long way off.
Everyone else in that meeting room had several papers in top-tier journals, a few distinguished youth projects, several improved surgical techniques, and foundational publications to their name.
For Wu Ting’s appointment as group leader to be possible, let alone persuasive, he would need to achieve several things before the annual conference. With the help of the four hospitals, he would have to complete the phase three validation. He would also need to win the Jin Country Medical Science and Technology Award from the Jin Country Medical Association based on the results of the first three phases, creating widespread social impact. Finally, he would have to present the theoretical research for phase four and truly establish a systematic radical cure.
With Scholar Zeng’s promise and approval, the course was set.
After bidding farewell to Ma Mengchao, the directors immediately returned to Fan City.
The four directors went straight to find Wu Ting.
In his deputy director’s office in the Hepatic Tumor Surgery department at Fan City First Hospital, Wu Ting received the four senior doctors, with whom he was quite close.
Fu Jinfen and the other directors, not wanting to put too much pressure on Wu Ting, didn’t reveal the entire plan.
They only discussed the initial phase.
"Wu Ting, after observing your phase three surgery and carefully reviewing the postoperative follow-up data from your team and Professor Long for the first two phases, we’ve come to a decision."
"Our four hospitals want to cooperate with you to complete this third phase of clinical validation. We want to adopt the new drug you developed, Fengmu Tiada, and introduce the phase three treatment technique into our departments."
"After that, each of our teams will form a dedicated medical group to assist you in completing phase three. We’ll feed all surgical data and postoperative follow-up information back to you."
Hearing the four directors’ plan, Wu Ting was overjoyed. This was incredibly good news.
Wu Ting was already fully confident in his phase three therapy. The only limitation was that due to Fan City First Hospital’s industry influence and reputation among patients, the number of patients he could admit was finite. Now, with the support of the four top hospitals in the Central Region, the clinical validation for this phase would undoubtedly accelerate dozens of times over.